1. recipient of any number of doses of any covid vaccine product other than the moderna covid-19 vaccine or the pfizer-biontech covid-19 vaccine 2. recipient of any organ other than a kidney 3. known current or prior donor specific antibody (dsa) 4. any change in transplant immunosuppression regimen (drug or dose) in response to suspected or proven rejection within the last 6 months 5. known diagnosis of covid-19 since last antibody test 6. receipt of a monoclonal antibody product or convalescent plasma within the last 30 days 7. known history of hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances. (components listed in section 6, and the cov2 and as03 investigator's brochure) 8. bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating intramuscular (im) vaccination based on investigator's judgment 9. moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature \>=38.0°c \[\>=100.4°f\]). a prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided 10. receipt of any vaccine in the 30 days preceding the study vaccine or planned vaccines in the 30 days following the study vaccine 11. estimated glomerular filtration rate \<30ml/min/1.73m\^2 12. receipt of any cellular depleting agent (e.g. antithymocyte globulin (atg), rituximab, alemtuzumab, cyclophosphamide) within 12 months preceding enrollment 13. receiving systemic immunomodulatory medication(s) for any condition other than transplant 14. any uncontrolled active infection 15. infection with human immunodeficiency virus (hiv) 16. maintenance immunosuppressive regimen that includes anything other than a cni, mycophenolate/mycophenolate mofetil, and =\< 5mg/day prednisone or equivalent 17. recent (within one year) or ongoing treatment for malignancy, except for definitive surgical treatment of localized skin cancers 18. any unstable acute or chronic illness, treatments, or findings which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the c candidate's ability to comply with study requirements or may impact the quality or interpretation of the data obtained from the study

1. recipient of any number of doses of any covid vaccine product other than the moderna covid-19 vaccine or the pfizer-biontech covid-19 vaccine 2. recipient of any organ other than a kidney 3. known current or prior donor specific antibody (dsa) 4. any change in transplant immunosuppression regimen (drug or dose) in response to suspected or proven rejection within the last 6 months 5. known diagnosis of covid-19 since last antibody test 6. receipt of a monoclonal antibody product or convalescent plasma within the last 30 days 7. known history of hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances. (components listed in section 6, and the cov2 and as03 investigator's brochure) 8. bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating intramuscular (im) vaccination based on investigator's judgment 9. moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature \>=38.0°c \[\>=100.4°f\]). a prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided 10. receipt of any vaccine in the 30 days preceding the study vaccine or planned vaccines in the 30 days following the study vaccine 11. estimated glomerular filtration rate \<30ml/min/1.73m\^2 12. receipt of any cellular depleting agent (e.g. antithymocyte globulin (atg), rituximab, alemtuzumab, cyclophosphamide) within 12 months preceding enrollment 13. receiving systemic immunomodulatory medication(s) for any condition other than transplant 14. any uncontrolled active infection 15. infection with human immunodeficiency virus (hiv) 16. maintenance immunosuppressive regimen that includes anything other than a cni, mycophenolate/mycophenolate mofetil, and =\< 5mg/day prednisone or equivalent 17. recent (within one year) or ongoing treatment for malignancy, except for definitive surgical treatment of localized skin cancers 18. any unstable acute or chronic illness, treatments, or findings which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the c candidate's ability to comply with study requirements or may impact the quality or interpretation of the data obtained from the study

recipient of any number of doses of any covid vaccine product other than the moderna covid-19 vaccine or the pfizer-biontech covid-19 vaccine recipient of any organ other than a kidney known current or prior donor specific antibody (dsa) any change in transplant immunosuppression regimen (drug or dose) in response to suspected or proven rejection within the last 6 months known diagnosis of covid-19 since last antibody test receipt of a monoclonal antibody product or convalescent plasma within the last 30 days known history of hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances. (components listed in section 6, and the cov2 and as03 investigator's brochure) bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating intramuscular (im) vaccination based on investigator's judgment moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature >=38.0°c [>=100.4°f]). a prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided receipt of any vaccine in the 30 days preceding the study vaccine or planned vaccines in the 30 days following the study vaccine estimated glomerular filtration rate <30ml/min/1.73m^2 receipt of any cellular depleting agent (e.g. antithymocyte globulin (atg), rituximab, alemtuzumab, cyclophosphamide) within 12 months preceding enrollment receiving systemic immunomodulatory medication(s) for any condition other than transplant any uncontrolled active infection infection with human immunodeficiency virus (hiv) maintenance immunosuppressive regimen that includes anything other than a cni, mycophenolate/mycophenolate mofetil, and =< 5mg/day prednisone or equivalent recent (within one year) or ongoing treatment for malignancy, except for definitive surgical treatment of localized skin cancers any unstable acute or chronic illness, treatments, or findings which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the c candidate's ability to comply with study requirements or may impact the quality or interpretation of the data obtained from the study

recipient of any number of doses of any covid vaccine product other than the moderna covid-19 vaccine or the pfizer-biontech covid-19 vaccine recipient of any organ other than a kidney known current or prior donor specific antibody (dsa) any change in transplant immunosuppression regimen (drug or dose) in response to suspected or proven rejection within the last 6 months known diagnosis of covid-19 since last antibody test receipt of a monoclonal antibody product or convalescent plasma within the last 30 days known history of hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances. (components listed in section 6, and the cov2 and as03 investigator's brochure) bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating intramuscular (im) vaccination based on investigator's judgment moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature >=38.0°c [>=100.4°f]). a prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided receipt of any vaccine in the 30 days preceding the study vaccine or planned vaccines in the 30 days following the study vaccine estimated glomerular filtration rate <30ml/min/1.73m^2 receipt of any cellular depleting agent (e.g. antithymocyte globulin (atg), rituximab, alemtuzumab, cyclophosphamide) within 12 months preceding enrollment receiving systemic immunomodulatory medication(s) for any condition other than transplant any uncontrolled active infection infection with human immunodeficiency virus (hiv) maintenance immunosuppressive regimen that includes anything other than a cni, mycophenolate/mycophenolate mofetil, and =< 5mg/day prednisone or equivalent recent (within one year) or ongoing treatment for malignancy, except for definitive surgical treatment of localized skin cancers any unstable acute or chronic illness, treatments, or findings which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the c candidate's ability to comply with study requirements or may impact the quality or interpretation of the data obtained from the study